RGNX — Regenxbio Inc

Stock analysis, trade plans, and proprietary indicators by Trend Edge.

Trend Edge Setup Score

Trend Edge rates RGNX Bearish with a Setup Score of 22, net conviction 21, actionability 24. How the Setup Score works →

Total Setup Score22
Directional BiasBearish
Net Conviction21
Actionability24 (in range)

Key signals behind this score

About Regenxbio Inc

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chron… Read full Trend Edge analysis →

Trend Edge Proprietary Indicators

Key Metrics

Current Price$8.91
Market Cap$730M
Float57.3M
Shares Outstanding66.0M
Price/Sales (TTM)4.18
vs. Analyst Target+175.5% to analyst PT
Profit Margin-112.58%
Operating Margin (TTM)27.09%
Revenue (TTM)$174M
Dividend RateNone
Analyst Target Price$24.55 (12 analysts)

Financial History

Annual Revenue & Earnings History

YearRevenueNet IncomeGross ProfitEBITDA
2020 $155M -$111M $119M -$96.8M
2021 $470M $128M $419M $177M
2022 $113M -$280M $58.2M -$244M
2023 $90.2M -$263M $53.0M -$239M
2024 $83.3M -$227M $49.8M -$198M
2025 $170M -$194M $150M -$133M

Recent Quarterly Revenue & Net Income

QuarterRevenueNet Income
Sep 2025 $29.7M -$61.9M
Dec 2025 $30.3M -$67.1M
Mar 2026 $6.4M -$90.1M
Jun 2026 $108M $22.7M

Ownership & Float

Insider Ownership6.3%
Institutional Ownership65.5%
Short Float12.5%
% of All Funds Holding1.86%
Number of Funds Holding164

Current Moving Averages

Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.

TimeframeSMAValueTrend Context
Weekly10-Week SMA$10.81Near-term / short-term trend
Weekly40-Week SMA$10.19Medium-term trend
Weekly80-Week SMA$9.59Cyclical trend (business cycle)
Weekly200-Week SMA$13.67Secular trend (multi-year)
Monthly10-Month SMA$10.29Near-term monthly trend
Monthly20-Month SMA$9.56Medium-term monthly trend
Monthly40-Month SMA$12.19Secular monthly trend

Volume Shelves — Support & Resistance

Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.

Price LevelTypeVolume RatioAge
$11.80 resistance 1.97x 0 months ago
$7.00 support 2.27x 1 months ago
$14.60 resistance 1.25x 6 months ago
$14.50 resistance 1.20x 25 months ago

Historical Earnings Reactions (44 events)

TimeframeAvg ReturnMedianWin RateBestWorst
Gap -0.28% -0.17% 43.18% 9.09% -12.64%
1 Day 0.10% -0.62% 47.73% 18.66% -20.88%
1 Week 3.39% 2.53% 56.82% 29.46% -30.41%
2 Weeks 1.63% 0.47% 52.27% 28.40% -30.91%
1 Month 4.33% 3.50% 58.14% 44.01% -32.24%

Next earnings: October 25, 2026 (59 days away)

Seasonality & Day-of-Week Patterns

Monthly Seasonality

MonthAvg ReturnWin RateSamples
Jan-9.1%36.4%11
Feb0.1%27.3%11
Mar0.7%54.5%11
Apr3.9%63.6%11
May-4.0%27.3%11
Jun10.8%63.6%11
Jul-1.9%36.4%11
Aug1.8%40.0%10
Sep7.1%60.0%10
Oct-6.1%36.4%11
Nov16.5%72.7%11
Dec-5.1%36.4%11

Day-of-Week Tendencies

DayAvg ReturnWin RateSamples
Monday 0.04% 47.6% 515
Tuesday 0.07% 50.5% 566
Wednesday 0.38% 51.2% 563
Thursday -0.33% 46.7% 553
Friday 0.09% 50.6% 551

Top Institutional Holders

Institutional holder breakdown coming soon.

Total institutional ownership: 65.5%

Insider Transactions — Smart Summary

Total insider ownership: 6.3%

12-Month Insider Activity Summary

Total Filings7
Net Value-$1.1M
Net Shares Change-76,210
% of Float-0.1%
C-Suite Filings7
Clusters Detected0

Key Insiders

NameTitleNet ValueFilingsActivity
PAKOLA STEVE Chief Medical Officer -$634,326.084 4 N/A
Simpson Curran Chief Executive Officer -$416,598.22 3 N/A

Significant Filings

DateInsiderTitleNet ValuePrice After
2026-07-01 PAKOLA STEVE Chief Medical Officer -$400,096.924 Transaction at $10.04, now -11.3%
2026-05-13 PAKOLA STEVE Chief Medical Officer -$168,705.18 Transaction at $11.02, now -19.1%
2025-10-10 Simpson Curran Chief Executive Officer -$262,634.82 Transaction at $12.62, now -29.4%
2026-03-12 PAKOLA STEVE Chief Medical Officer -$53,033.4 Transaction at $10.35, now -13.9%
2025-10-01 Simpson Curran Chief Executive Officer -$76,468.72 Transaction at $10.03, now -11.2%
2025-09-12 Simpson Curran Chief Executive Officer -$77,494.68 Transaction at $10.02, now -11.1%

View full insider transaction history on Trend Edge →

AI Consult Analysis

Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Regenxbio Inc (RGNX) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).

AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.

Get the full AI Consult analysis for RGNX on Trend Edge →